SEPN — Septerna, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1984086 ·
Last close
$40.02
Market Cap
$1.90B
52W High
$53.34
52W Low
$21.31
ADV30
429,915
Next earnings
—
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 18,881,000 — -27,229,000 -26,590,000 619,404,000 167,124,000 191,475,000
Jun 2026 26,746,000 — -16,836,000 -13,034,000 566,737,000 84,662,000 180,016,000
Mar 2026 26,523,000 — -13,300,000 -8,637,000 569,688,000 71,605,000 191,230,000
Dec 2025 24,118,000 — -16,023,000 -10,738,000 596,187,000 120,722,000 214,261,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-76,568,000
Investing CF
$-157,223,000
Financing CF
$80,926,000
CapEx
$-1,037,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.29
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-215,514,000
Inventory
—
Receivables
$21,879,000
ST Investments
$311,477,000
EBIT TTM
$-73,388,000
Pretax Income TTM
$-53,056,000
Interest Exp TTM
—
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$96,268,000
EBITDA
$-71,745,000
Free Cash Flow
$-7,808,500
Enterprise Value
$1,568,988,928
Total Cash
$478,600,992
Total Debt
$21,993,000
Shares Out
47,549,223
Trailing EPS
$-1.30
Book Value
$9.03
ROE
-14.4%
ROA
-7.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 45,951,000 -80,797,000 -48,879,000 596,187,000 214,261,000 381,926,000 110,189,000
Dec 2024 1,075,000 -80,823,000 -71,798,000 456,554,000 36,507,000 420,047,000 -67,470,000
Dec 2023 151,000 -45,550,000 4,180,000 130,867,000 169,241,000 -38,374,000 -38,723,000
Dec 2022 0 -27,967,000 -27,676,000 36,119,000 80,320,000 -44,201,000 -23,303,000

TTM Snapshot

Revenues TTM
$98,882,000
NetIncome TTM
$-24,236,000
OpCashFlow TTM
—
Assets (Latest)
$566,737,000
Forward EPS
$-1.67

Peers — same industry

TickerNameMarket CapLastDaily %
VERA Vera Therapeutics, Inc. $1.89B $26.20 —
ZBIO Zenas BioPharma, Inc. $1.88B $27.75 —
TRVI Trevi Therapeutics, Inc. $1.93B $13.51 —
HMDCF HUTCHMED (China) Ltd $1.88B $2.16 —
HRMY Harmony Biosciences Holdings, Inc. $1.94B $33.01 —

News headlines (Yahoo Finance, 1h cache)

Septerna (SEPN) Stock Sees Fair Value Lift As Analysts Raise SEP 479 Expectations
2026-11-13 03:17 · Yahoo
What Septerna Shares Profit To Loss Swing Means For Shareholders
2026-11-10 07:08 · Yahoo
Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates
2026-11-09 21:35 · Yahoo
Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results
2026-11-09 21:01 · Yahoo
Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting
2026-11-04 13:00 · Yahoo
Septerna to Participate in Upcoming Investor Conferences
2026-11-03 13:00 · Yahoo
Is Septerna (SEPN) Stock Too Rich, Or Still Reasonable?
2026-10-28 20:07 · Yahoo
Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?
2026-09-14 14:10 · Yahoo
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-10 20:00 · Yahoo
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
2026-08-25 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.